Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DNC Daewoong Derma & Plastic Surgery Network (DNC Aesthetics) is a specialized medical aesthetics subsidiary of Daewoong Pharmaceutical, founded in 2001. The company provides a comprehensive "total solution" for aesthetic procedures, encompassing botulinum toxins, dermal fillers, absorbable threads, and regenerative medicine products. Its flagship offerings include the botulinum toxin Nabota and various filler brands like DCLASSY and Volassom. DNC is a leader in the K-aesthetic market and has expanded significantly into Southeast Asia, particularly Indonesia, where it operates clinics and training centers. The company also manages the DEEP (Daewoong Medical-Aesthetic Expert Program) to provide clinical education and standardized protocols for medical professionals globally. In 2025, the company integrated more closely with CGbio to strengthen its regenerative aesthetics portfolio.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Daewoong Derma & Plastic Surgery Network.